Base Editing Achieves High Efficiency in Human Embryos but Raises Safety Concerns

Key points

• Researchers delivered the base editor ABE8e-V106W as a protein at fertilization, achieving editing at all PCSK9 alleles in human embryos.
• Edited embryos developed normally to the blastocyst stage, and homozygous edited stem cell lines were successfully derived.
• Unlike Cas9-induced double-strand breaks, which cause frequent aneuploidy and large deletions, base editor-induced lesions were efficiently repaired with no insertions or deletions detected.
• However, rare on-target chromosome breakage and chromosomal abnormalities were observed, and editing at bystander and off-target sites was mosaic.
• Delivering the editor as mRNA caused frequent embryo arrest due to guide-independent deaminase activity, highlighting significant safety risks.
• The study concludes that while base editing is more precise than Cas9, undesirable genomic and developmental consequences currently preclude its clinical use in reproduction.

Background

This research follows previous concerns about gene therapy safety, such as the 2025 death of a child in China from an experimental base-editing trial, which raised questions about oversight. It also builds on recent advancements in understanding human embryonic development, including studies on epigenome mapping and gene regulation in cortical development, which highlight the complexity of early human biology.

Why it matters

This study provides critical insights into the safety and efficacy of base editing in human embryos, a key technology for potential genetic therapies. While it shows promise for correcting diseases like high cholesterol (via PCSK9 editing), the identified risks of off-target edits and chromosomal abnormalities underscore the need for further refinement before clinical application. This work helps shape ethical and regulatory frameworks for germline editing.

What to watch

Researchers will likely focus on improving the precision and safety of base editors to minimize off-target effects and chromosomal abnormalities. Further studies may explore alternative delivery methods to avoid the embryo arrest seen with mRNA delivery. Regulatory bodies may also review these findings to update guidelines on human embryo editing.